Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Mann, der ein Lithium-Unternehmen im Wert von 1,2 Milliarden Dollar aufgebaut hat, ist zurück...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWWP | ISIN: US34960Q3074 | Ticker-Symbol: CNB1
NASDAQ
10.10.25 | 21:59
2,705 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FORTRESS BIOTECH INC Chart 1 Jahr
5-Tage-Chart
FORTRESS BIOTECH INC 5-Tage-Chart

Aktuelle News zur FORTRESS BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.10.FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln9
02.10.Fortress Biotech stock faces setback as FDA issues CRL for CUTX-1013
01.10.Fortress Biotech stock plummets after FDA rejects Menkes disease drug13
01.10.Fortress Biotech plunges as FDA rejects rare disease drug12
FORTRESS BIOTECH Aktie jetzt für 0€ handeln
01.10.Fortress Biotech, Inc. - 8-K, Current Report5
01.10.Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing81Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange...
► Artikel lesen
01.10.Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101103MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S....
► Artikel lesen
21.08.Fortress Biotech stock price target lowered to $17 at H.C. Wainwright26
14.08.Fortress Biotech, Inc. - 10-Q, Quarterly Report2
14.08.Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights392Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right...
► Artikel lesen
16.07.Fortress Biotech, Inc. - 8-K, Current Report4
23.06.Fortress Biotech, Inc. - 8-K, Current Report1
05.06.Fortress Biotech, Inc. - 8-K, Current Report1
30.05.Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics257MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
► Artikel lesen
15.05.Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights405Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint...
► Artikel lesen
16.04.Fortress Biotech, Inc. - 8-K, Current Report2
31.03.Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights137Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary...
► Artikel lesen
17.03.Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform229FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic...
► Artikel lesen
27.01.Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT253Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
► Artikel lesen
06.01.Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease450Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1